Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates
about
Drug-induced reactivation of apoptosis abrogates HIV-1 infectionPrediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivoA new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidineIn vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidineAlkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistanceCoresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile anThe nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitorsDrug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory TrialThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidineY586F mutation in murine leukemia virus reverse transcriptase decreases fidelity of DNA synthesis in regions associated with adenine-thymine tracts.Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.Clinical relevance of viral dynamics and genotypes in hepatitis B virus.Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSZidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.Functional and structural dynamics of hepadnavirus reverse transcriptase during protein-primed initiation of reverse transcription: effects of metal ions.Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.Mutations in the RNase H primer grip domain of murine leukemia virus reverse transcriptase decrease efficiency and accuracy of plus-strand DNA transfer.The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet.Review: Present and future directions in the treatment of chronic hepatitis B infection.Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.Synthesis and anti-HIV activity of [d4U]-[trovirdine analogue] and [d4T]-[trovirdine analogue] heterodimers as inhibitors of HIV-1 reverse transcriptase.Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.
P2860
Q21090718-2D0903C9-8D71-40C4-A2FE-BC02F6A7BE35Q24535740-6D08CB52-7A05-4858-85B2-1ADE00AC332FQ28343476-5A54879A-E07B-4A8A-9D00-E224E7CDD9F7Q28344355-748356EB-63CC-4259-8396-81407DC540D5Q28365182-C7832AF1-7133-4583-8D62-62E5E5799471Q28369167-372C0162-9F3A-4313-8BDF-46D430F8FA8EQ28378760-DBC12047-3F41-4AEB-8B8B-B309BAF0B283Q28379139-0AD0CD48-F760-4AD4-9627-0132E2A7A501Q28552171-C1844F8B-8F8F-4088-BACC-F81D86356250Q33889635-5E67FBC4-7E1E-457E-88F1-51FEB194BEDDQ33935229-93FA0BD4-9B25-4175-A6E9-1789F0EF8BA9Q34099109-B981AE43-43BF-42F0-9F6D-CBBBD58AAA2DQ34251987-6F9AA999-B3F8-44B9-9E39-7905C729225AQ34996622-9A885EC6-7166-4743-A6B8-BCE6283ECCD8Q35020824-F11E4B2E-B894-4B77-B99E-037A48A74AD5Q35129803-A9E778E1-48D4-498A-BA63-0BC8B217A1B6Q35870930-524A2D83-2E6B-420C-AC3B-E20E71921F7AQ36673242-D15E618E-FDB6-4CCE-BC1E-D586970FECDBQ36928993-9989D453-FC55-4DBE-8F41-F7769DF8F8CAQ37747347-BF24EC52-A0B2-4057-9D80-8191B8511E18Q38307044-9B88ED6E-4764-4CDA-91E4-B28C63399972Q38351813-5804BA84-B44F-4969-9B09-E8D8472C5A92Q39730755-A0DA6CA7-D943-4280-A3C0-0D33D958EBBEQ40748250-3837B368-0DBF-4023-8E2A-49726CFD02D3Q40866538-4D2AC152-C350-488A-9195-2A324538BFDDQ40883043-2321B443-D404-47B7-B066-61D225373455Q41495257-4C0E7514-CF0F-41FA-9F1F-8D471E720E4DQ41748484-B8848DBF-9428-4080-A82F-36B7997E2631Q41879018-D2FF8BA7-4CC6-42F3-9661-A1C0BEB0CC4AQ41892773-41DA4368-8FE4-4E58-B1AD-0422F85EF0E0Q42062012-B63694B2-8289-48DA-8676-04FB6256FB91Q42917410-2D95E15A-17B0-4DEB-A748-CE39408C6825Q44250812-D3D416B7-7125-4E07-8B3B-BAF2BA8E5076Q54057730-21421A6F-FA01-4E90-8592-2E4929A23E11
P2860
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates
description
1995 nî lūn-bûn
@nan
1995 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Novel mutations in reverse tra ...... boratory and clinical isolates
@ast
Novel mutations in reverse tra ...... boratory and clinical isolates
@en
Novel mutations in reverse tra ...... boratory and clinical isolates
@nl
type
label
Novel mutations in reverse tra ...... boratory and clinical isolates
@ast
Novel mutations in reverse tra ...... boratory and clinical isolates
@en
Novel mutations in reverse tra ...... boratory and clinical isolates
@nl
prefLabel
Novel mutations in reverse tra ...... boratory and clinical isolates
@ast
Novel mutations in reverse tra ...... boratory and clinical isolates
@en
Novel mutations in reverse tra ...... boratory and clinical isolates
@nl
P2093
P2860
P3181
P356
P1476
Novel mutations in reverse tra ...... boratory and clinical isolates
@en
P2093
D L Mayers
J W Mellors
R F Schinazi
P2860
P304
P3181
P356
10.1128/AAC.39.5.1087
P407
P577
1995-05-01T00:00:00Z